Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma

Authors :: Bing Zhu
Xinyan Wang
Takaya Shimura
Andrew C Huang
Nana Kong
Yujie Dai
Jianmin Fang
Peng Guo
Jie-Er Ying
Source :: npj Precision Oncology, Vol 7, Iss 1, Pp 1-13 (2023)
Publication Year :: 2023
Publisher :: Nature Portfolio, 2023.
Abstract: Abstract As a highly lethal adenocarcinoma of the hepatobiliary system, outcomes for cholangiocarcinoma (CCA) patients remain prominently poor with a 5-year survival of

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools